Health

  • February 02, 2026

    Urgent Care Co. Carbon Health Hits Ch. 11 With $100M+ Debt

    Carbon Health Technologies Inc., an urgent care provider based in California, filed for Chapter 11 bankruptcy relief Monday in Texas, listing more than $100 million in liabilities.

  • February 02, 2026

    Norton Rose Grows In Key Cities By Adding 5 Polsinelli Attys

    Norton Rose Fulbright announced Monday that it has added five former Polsinelli PC shareholders as partners to grow its transactional and healthcare capabilities in two key U.S. markets.

  • January 30, 2026

    3rd Circ. Preview: Privacy Issues Top Feb. Argument Lineup

    Issues involving privacy feature prominently on the Third Circuit's February oral argument schedule, with panels set to hear a dispute regarding an optometry business's duty to protect private data belonging to third-party customers, and a case over whether the city of Philadelphia can be sued by a mother after a police officer shared images of her son's death from the scene where he committed suicide.

  • January 30, 2026

    2nd Circ. Affirms $2.8M Award In Ex-NFL Player's PPE Suit

    The Second Circuit declined Friday to let a New York real estate attorney escape from a roughly $2.8 million arbitration award to a former NFL linebacker after a deal to purchase and distribute medical gloves went sour, holding that the arbitrator did not exceed her authority or botch the process.

  • January 30, 2026

    Sentara Health Can't Escape Suit Over Stable Value Fund

    A Virginia federal judge said Friday that Sentara Health can't dodge a suit claiming it failed to kick an underperforming investment fund from its retirement plan, ruling the healthcare system hasn't shown it assessed the fund with the proper due diligence to beat the case.

  • January 30, 2026

    Planned Parenthood Drops Medicaid Fight After 1st Circ. Loss

    Planned Parenthood abandoned a legal challenge to a ban on Medicaid reimbursements for its clinics Friday, following a loss at the First Circuit, which upheld the ban in December.

  • January 30, 2026

    Dozens Of Cases Linking Zantac To Cancer Thrown Out

    A Delaware state trial judge tossed over 200 cases by individuals alleging Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, ruling the claims were time-barred.

  • January 30, 2026

    Labor Dept. Recovered $1.4B For Benefit Plans In Fiscal '25

    The U.S. Department of Labor reported $1.4 billion in recoveries for employee benefit plans in its latest enforcement report on Friday, an amount equal to what the agency has reported for the previous three fiscal years, although it had a significant uptick in funds recovered from abandoned plans.

  • January 30, 2026

    Drugmakers Ask To Appeal Overarching Conspiracy Claim

    A group of pharmaceutical companies that failed to secure a pretrial win on an overarching conspiracy claim in a sprawling generic-drug antitrust enforcement action is asking a Connecticut federal judge to let them seek Second Circuit review, saying the ruling raises a novel legal issue.

  • January 30, 2026

    SelectQuote Execs Face Investor Suit Over Kickback Probe

    Executives and directors of insurance comparison platform SelectQuote were hit with a shareholder's derivative suit accusing them of concealing a kickback scheme currently subject of a False Claims Act suit by the U.S. Department of Justice.

  • January 30, 2026

    FTC Requires Facility Sales For $835M Healthcare Deal

    The Federal Trade Commission reached an agreement Friday allowing Sevita Health to move ahead with an $835 million deal for BrightSpring Health Services Inc.'s community living business, conditioned on the sale of more than 100 facilities.

  • January 30, 2026

    Allergan Sued Over 'Preservative Free' Eyedrop Labeling

    AbbVie unit Allergan USA was hit with a proposed false advertising class action Wednesday in Illinois state court by two customers alleging that the company labeled its eyedrops as "preservative free" despite the fact that they contain boric acid. 

  • January 30, 2026

    Feds Say Alleged $100K H-1B Fee Harm Only Speculative

    The Trump administration asked a California federal judge to dismiss a suit challenging President Donald Trump's $100,000 H-1B visa fee, arguing it rests upon multiple what-ifs that deprive the groups that challenged the fee of standing.

  • January 30, 2026

    Attys Rip Judge-Shopping Sanctions As Bid To 'Rewrite' Rules

    Two Alabama attorneys who were sanctioned for allegedly judge shopping in a civil rights case urged the Eleventh Circuit to toss the sanctions Friday, arguing the judges accusing them were seeking to "rewrite" the Federal Rules of Civil Procedure.

  • January 30, 2026

    1st Circ. Revives Ex-Hasbro Workers' Religious Vax Bias Suit

    Two former Hasbro employees who sought religious exemptions from the company's COVID-19 vaccination policy plausibly alleged they were disciplined because of their accommodation requests, the First Circuit ruled, reviving the workers' retaliation and discrimination suit.

  • January 30, 2026

    Drug Cos. Want Rethink Of DQ Bid Targeting Ex-Prosecutor  

    More than two dozen pharmaceutical companies accused of fixing generic-drug prices have again asked a Pennsylvania federal judge to disqualify a former Connecticut assistant attorney general now in private practice from representing insurers Humana Inc. and Molina Healthcare Inc. in a sprawling multidistrict litigation proceeding.

  • January 30, 2026

    Healthcare Group Of The Year: Sheppard Mullin

    Sheppard Mullin Richter & Hampton LLP attorneys advised Ascension in its $3.9 billion acquisition of AmSurg, served as lead transaction counsel for Prospect Medical's bankruptcy estate and advised nonprofit Scan Group in its strategic collaboration with Sutter Health, earning it a spot among the 2025 Law360 Healthcare Groups of the Year.

  • January 30, 2026

    Former CMS Deputy Moves To Baker Donelson

    The Trump administration's former Medicaid leader has affiliated himself with Baker Donelson Bearman Caldwell & Berkowitz PC as a strategic adviser, where the firm said he'll collaborate with its health and government solutions team across 12 states and the nation's capital.

  • January 30, 2026

    Mangione Won't Face Death Penalty, Judge Rules

    A Manhattan federal judge on Friday took the death penalty off the table for Luigi Mangione, dismissing a capital count and setting up an October trial that could see him go to prison for life without the possibility of release.

  • January 29, 2026

    Fitness App Must Face Trimmed Suit Over Tracking Cookies

    A California federal judge cut several wiretap and fraud claims from a proposed class action accusing MyFitnessPal of allowing third parties to track the browsing activities of website visitors who rejected the use of tracking cookies while allowing the plaintiffs to proceed with invasion of privacy and two other allegations.

  • January 29, 2026

    DOL Proposes Pharmacy Benefit Manager Fee Disclosure Rule

    The U.S. Department of Labor's employee benefits subagency Thursday proposed a rule to require new fee disclosures from pharmacy benefit managers, which act as intermediaries between drugmakers, pharmacies and insurers, to help managers of employee health plans ensure PBM services are reasonably priced.

  • January 29, 2026

    Pa. Nursing Home Disputes Patient Death Suits' Coverage Cap

    A Pennsylvania nursing home told a federal court that an insurer should pay up to $3 million in coverage for lawsuits by six patients' estates alleging a staff member murdered them, arguing the insurer misconstrued a state medical negligence statute in order to limit coverage.

  • January 29, 2026

    Conn. Drug Price Cap Survives Distributor Challenge, For Now

    The Second Circuit has declined a bid to immediately block the state of Connecticut from enforcing a cap on generic and off-patent drug prices while the Healthcare Distribution Alliance, a collection of wholesale distributors, challenges the new law.

  • January 29, 2026

    ITC To Review Medical Imaging Imports For Infringement

    The U.S. International Trade Commission said it is looking into medical imaging device imports for alleged patent infringement in response to a complaint from a Canadian-American firm.

  • January 29, 2026

    Teva Tries To Spike Paragard Trial Claims, Punitive Damages

    About a week into its first trial over the alleged dangers of the Paragard contraceptive, Teva Pharmaceuticals asked a Georgia federal judge Wednesday to cut the case short and hand it an early win, or at least let it out of a bid for punitive damages.

Expert Analysis

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Food Industry Braces For MAHA And Other Challenges In 2026

    Author Photo

    After the Make America Healthy Again movement kept the U.S. Food and Drug Administration under pressure in 2025, actions in the food safety space are likely to continue this year, including updated Supplemental Nutrition Assistance Program dietary guidelines and processed food definitions, say attorneys at Wiley.

  • Preparing For Congressional Investigations In A Midterm Year

    Author Photo

    2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.